Skip to main content

Advertisement

Fig. 2 | BMC Cancer

Fig. 2

From: Effect of sulfasalazine on human neuroblastoma: analysis of sepiapterin reductase (SPR) as a new therapeutic target

Fig. 2

SPR mRNA expression correlation with NB clinical parameters. Differential expression of SPR mRNA expression in the Kocak-649 cohort upon separation of patient samples into clinically important groups. (a) SPR expression is significantly higher in older than in younger patients (age at diagnosis ≥18 months versus <18 months; P = 1.9 · 10−23), (b) SPR expression is significantly higher in patients with than in patients without tumor MYCN gene amplification (P = 7.9 · 10−15), and (c) SPR expression is significantly higher in high than in low stage tumors (INSS stage 3 and 4 versus stage 1, 2, and 4S; various P < 0.05). For all three parameters, SPR expression is highest in the poor outcome group. Statistical analysis was performed using the non-parametric Kruskal-Wallis tests

Back to article page